A2 Biotherapeutics, a US-based developer of cell therapies for the treatment of solid tumours, has closed a $71.5m series B round featuring Hartford HealthCare Endowment, the philanthropic arm of healthcare provider Hartford HealthCare.
Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital and Euclidean Capital also took part in the round along with UC Investments, part of University of California’s Office of the Chief Investment Officer of the Regents.
Founded in 2018, A2 is working on cell therapies designed to destroy cancer tumours while keeping the genome of healthy cells intact. The funding will go to clinical development of its first three drug candidates in preparation for a first-in-human study in 2022.
The company said it has now raised $136m in total, including $57m in series A funding from investors including Vida Ventures, Column Group, Samsara BioCapital and Nextech Invest in November 2019. Viva Ventures’ website dates its first investment in A2 at April 2018.
The original version of this article appeared on our sister site, Global University Venturing.